WAVE LIFE SCIENCES LTD (WVE)

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration;...

Relative Strength Alert For Wave Life Sciences

WVE Crosses Below Key Moving Average Level

Commit To Buy Wave Life Sciences At $5, Earn 34.6% Annualized Using Options

Wave Life Sciences to Present at Upcoming Investor Conferences

WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023

WVE stock results show that WAVE Life Sciences beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

WVE Stock Earnings: WAVE Life Sciences Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips WAVE Life Sciences (NASDAQ:WVE) just reported results for the fourth quarter of...

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking...

BMO starts Korro at outperform, cites upcoming data for AATD drug (NASDAQ:KRRO)

BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.

WVE Makes Bullish Cross Above Critical Moving Average

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are...

Relative Strength Alert For Wave Life Sciences

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Commit To Purchase Wave Life Sciences At $5, Earn 29.5% Annualized Using Options

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering...

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data...

Investors Grab WVE 10.8% Cheaper Than Its Secondary Stock Offering

Notable Two Hundred Day Moving Average Cross - WVE

Mizuho says market 'doesn't understand' Wave capital raise (NASDAQ:WVE)

Mizuho says the market "doesn't understand" the recent capital raise by Wave Life Sciences (WVE) that triggered a major selloff in the stock. Read more here.